In a patient with acute renal failure, serum digoxin concentrations may anomalously rise after discontinuation, highlighting the need for careful therapeutic drug monitoring in uremia.
Answers are grounded in this paper and cite their sources.
Anomalous digoxin rises may occur post-discontinuation in uremia; hypothesis-generating for TDM protocols in renal failure.
Brief Reports1 April 1983Anomalous Serum Digoxin Concentrations in UremiaJEFFREY L. CRAVER, M.D., ROLAND VALDES Jr., Ph.D.JEFFREY L. CRAVER, M.D.Search for more papers by this author, ROLAND VALDES Jr., Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-4-483 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen digoxin therapy is discontinued, it is generally assumed that the patient's serum concentration of the drug will decrease over time with a half-life dependent on the rate of digoxin elimination. A few reports (1, 2) have noted deviations from this prediction. We describe a patient with acute renal failure who had an unanticipated twofold rise in his apparent serum concentration of digoxin during the 9 days after the last administered dose of this drug.A 56-year-old black man with hypertension was hospitalized for atrial fibrillation complicated by embolic small bowel infarction. Several surgical procedures prolonged his hospitalization. An intravenous...References1. DAHLQVISTEJVINSSONSCHENCK-GUSTAFSSONK RG. Effect of quinidine on plasma concentration and renal clearance of digoxin: a clinically important drug reaction. Br J Clin Pharmacol. 1980;9:413-8. CrossrefMedlineGoogle Scholar2. SZEFLERKOUPGIACOIA SJG. Paradoxical behavior of serum digoxin concentrations in an anuric neonate. J Pediatr. 1977;91:487-9. CrossrefMedlineGoogle Scholar3. GAULTSUGDENMALONEYAHMEDTWEEDDALE MDCMM. Biotransformation and elimination of digoxin with normal and minimal renal function. Clin Pharmacol Ther. 1979;25:499-513. CrossrefMedlineGoogle Scholar4. GIBSONNELSON TH. The question of cumulation of digoxin metabolites in renal failure. Clin Pharmacol Ther. 1980;27:219-23. CrossrefMedlineGoogle Scholar5. GAULTKALRALONGERICHDAWE HJLM. Digoxigenin biotransformation. Clin Pharmacol Ther. 1982;31:695-704. CrossrefMedlineGoogle Scholar6. REUNINGSAMSNOTARI RRR. Role of pharmacokinetics in drug dosage adjustment: I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol. 1973;13:127-41. Google Scholar7. GRUBERWHITAKERBUCKALEW KJV. Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature. 1980;287:743-5. CrossrefMedlineGoogle Scholar8. ACKERMANDOHERTYFLANIGAN GJW. Peritoneal dialysis and hemodialysis of tritiated digoxin. Ann Intern Med. 1967;67:718-23. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JEFFREY L. CRAVER, M.D.; ROLAND VALDESJr., Ph.D.Affiliations: The Jewish Hospital of St. Louis Washington University School of Medicine St. Louis, Missouri PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySignificant Improvement in Digoxin Immunoassays Over Four Decades: Newer Assays are Less Affected by InterferencesImmunoassays and Issues With Interference in Therapeutic Drug MonitoringAdvances in understanding the role of cardiac glycosides in control of sodium transport in renal tubulesImpact of Interferences Including Metabolite Crossreactivity on Therapeutic Drug Monitoring ResultsChallenges in Therapeutic Drug Monitoring of Digoxin Using ImmunoassaysChallenges in Therapeutic Drug Monitoring of Digoxin and Other Anti-Arrhythmic DrugsEffect of Spironolactone, Potassium Canrenoate and Their Common Metabolite Canrenone on Serum Digoxin Measurement by Digoxin III, a New Digoxin ImmunoassayDigoxinNew Enzyme-Linked Immunosorbent Digoxin Assay on the ADVIA?? IMS??? 800i System Is Virtually Free from Interference of Endogenous Digoxin-like Immunoreactive FactorsEndogenous and Exogenous Digoxin-like Immunoreactive SubstancesComparison of Microparticle Enzyme and Fluorescence Polarization Immunoassays in Pediatric Patients Not Receiving DigoxinComparability of a new turbidimetric digoxin test with other immunochemical tests and with HPLC—a multicenter evaluationDigoxin and Its Related Endogenous FactorsDigoxin-like immunoreactive substance in liver failure: effect of liver transplantation and relationship to presence of hepatic encephalopathyDigoxin Immune Fab Administration following an Unexplained Increase in Serum Digoxin ConcentrationCardiac Arrhythmias in End-Stage Renal Disease: Prevalence, Risk Factors, and ManagementFurther evidence for the dissociation of digoxin-like immunoreactivity from Na+, K+-ATPase inhibitory activityDigoxin-like Immunoreactive Substances in the Plasma of Intensive Care Unit Patients: Relationship to Organ DysfunctionConsiderations in the Diagnosis and Treatment of Arrhythmias in Patients with End-Stage Renal DiseaseDigoxin-like substance in the serum of uremic patients before and after hemodialysisMarked Digoxin-Likeimmunoreactive Factor Interference with an Enzyme ImmunoassayA Comparative Trial of Digoxin and Digitoxin in the Treatment of Congestive Heart FailurePathophysiological role of cation transport and natriuretic factors in hypertension.Therapeutic drug monitoring in cardiology: Recognizing pitfalls and problemsDelayed digoxin toxicity following discontinuance in acute renal failureInfluence of Assay Methodologies and Interferences on the Interpretation of Digoxin ConcentrationsMysterious Clusters of Deaths in HospitalsEndogenous Digitalis-Like FactorsThe Kidney in the Pathogenesis of Hypertension: The Role of SodiumDigoxin-Like Immunoreactive Substance in Postmortem Blood of Infants and ChildrenEvidence For A Circulating Sodium-Potassium Pump Inhibitor in Low Renin HypertensionCharacteristics of Hypertensive Patients With Increased Plasma Na + -K + Pump Inhibitory ActivitySpurious Results of Digoxin RadioimmunoassayAn Endogenous Digoxin-Like Substance in Patients with Renal ImpairmentSTEVEN W. GRAVES, Ph.D., BECKY BROWN, M.T., ROLAND VALDES Jr., Ph.D.Anomalous Serum Concentrations of DigoxinPAUL E. ROLAN, M.D., B.S., DEREK B. FREWIN, M.D., STEPHEN R. HAGLEY 1 April 1983Volume 98, Issue 4Page: 483-484KeywordsAtrial fibrillationAttentionDrug therapyDrugsHalf lifeHospital medicineHospitalizationsHypertensionInfarctionPathology and laboratory medicine ePublished: 1 December 2008 Issue Published: 1 April 1983 PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
JEFFREY L. CRAVER (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: